BPC-157

BPC-157 is a synthetic peptide of fifteen amino acids whose sequence corresponds to a partial fragment of a larger protein isolated from human gastric juice, described in the original literature as Body Protection Compound. Since the early 1990s it has become one of the most frequently published experimental peptides in the gastrointestinal and musculoskeletal injury literature, in nearly every case using rat or mouse models.

Two properties account for most of the research interest. The first is stability. Short peptides are typically degraded within minutes in the gut, and the source literature reports that this fragment remains intact in human gastric juice for extended periods without the terminal capping, cyclization, or carrier conjugation that comparable sequences usually require. The second is breadth. Investigators have reported effects in gastric and intestinal mucosa, tendon, ligament, skeletal muscle, bone, cornea, and vascular endothelium, which is a wider tissue range than most experimental peptides address.

That breadth is also the strongest reason to read the literature carefully rather than enthusiastically. A signal reported across many unrelated tissue systems, largely by one collaborative network, is a hypothesis that has not yet survived independent scrutiny. Response BioLabs supplies BPC-157 as a lyophilized powder for laboratory research use only. Nothing on this page describes a use in humans, and no human use is intended or supported.

The compound originates from work at the University of Zagreb School of Medicine, where Predrag Sikiric and colleagues characterized a protein present in human gastric juice that appeared to be associated with mucosal integrity. From that larger protein they identified a fifteen-residue region and synthesized it as a free peptide with the sequence GEPPPGKPADDAGLV. The designation 157 refers to the position of the fragment within the parent sequence as numbered in the original characterization.

Early experimental work through the 1990s used standard rodent gastric lesion models, including lesions induced by nonsteroidal anti-inflammatory agents, ethanol, and restraint stress. Through the 2000s the same group and its collaborators extended testing into transected Achilles tendon, transected medial collateral ligament, crushed skeletal muscle, segmental bone defects, and chemically induced colitis models. The peptide was also carried into pharmaceutical development under the code PL 14736 and entered early clinical evaluation for inflammatory bowel disease. Publicly available results from that program are limited, and no product derived from it reached regulatory approval in any jurisdiction.

From roughly 2015 onward the compound circulated well beyond academic laboratories, which produced a large volume of unverified claims that are not supported by the published record. In 2022 the World Anti-Doping Agency added BPC-157 to its Prohibited List under the category covering non-approved substances, a classification that reflects the absence of regulatory approval rather than a finding about performance. Researchers working with human subjects in any athletic context should treat that listing as a compliance fact, not a scientific one.

BPC-157 is a linear pentadecapeptide, molecular formula C62H98N16O22, average molecular weight 1419.54 g/mol, CAS number 137525-51-0. The sequence contains no cysteine residues, so there is no disulfide bond and no tertiary fold to preserve. It also contains four proline residues, three of them consecutive at positions three through five, which constrains backbone flexibility and is one of the structural features commonly proposed to explain its reported resistance to enzymatic cleavage.

The absence of a disulfide bridge simplifies handling considerably relative to peptides such as thymosin beta-4 analogues or cyclic constructs. There is no oxidation state to protect and no refolding step after reconstitution. The primary degradation routes of concern are hydrolysis of the peptide backbone in aqueous solution and deamidation at the aspartate residues at positions ten and eleven, both of which accelerate with temperature, with repeated freeze and thaw cycles, and at pH values away from mildly acidic to neutral.

Analytical characterization follows the ordinary standard for research peptides. Purity is determined by reversed-phase HPLC, typically reported at 99 percent or higher, and identity is confirmed by mass spectrometry against the expected monoisotopic mass. Researchers should note that a purity figure describes the fraction of peptide-related material that is the target sequence. It says nothing about residual solvent, counterion content, or water content, all of which affect the actual mass of active peptide in a stated quantity of powder. Certificates of analysis and third-party verification for each lot should be reviewed rather than assumed.

The most developed mechanistic hypothesis concerns angiogenic signaling. Several groups have reported that BPC-157 exposure upregulates vascular endothelial growth factor receptor 2 (VEGFR2) and increases downstream signaling through the Akt and endothelial nitric oxide synthase axis in cultured endothelial cells, with corresponding increases in vessel formation in rodent tissue after injury. Notably, this has been described as occurring without a proportional rise in VEGF ligand itself, which would place the interaction at the receptor rather than at ligand availability.

A second line of work concerns cell migration. In cultured tendon fibroblasts, exposure has been associated with increased phosphorylation and activation of focal adhesion kinase (FAK) and its substrate paxillin, the pathway that governs focal adhesion turnover and therefore how fast a cell can crawl across a substrate. Cell outgrowth from tendon explants and closure in scratch assays have been reported as consistent with that pathway readout.

Additional mechanisms proposed in the literature include modulation of the nitric oxide system, where effects have been reported in the presence of both nitric oxide synthase inhibitors and nitric oxide donors, suggesting an interaction with that system rather than simple agonism. Work in wound models has also reported effects on early growth response protein 1 (EGR-1) and its corepressor NAB2, transcriptional regulators of the granulation and collagen organization response. Separately, exposure has been associated with increased growth hormone receptor expression in cultured tendon fibroblasts, which would represent sensitization to an existing signal rather than a hormonal effect of the peptide itself. Rodent central nervous system work has reported interactions with dopaminergic and serotonergic systems along the brain-gut axis.

Every mechanism listed here is an observed association in a model system. None has been established as the operative pathway in an intact human, and no mechanistic claim from this literature should be carried forward as a description of what the compound does in people.

What is reasonably well established: BPC-157 is chemically stable relative to comparable short peptides, it is straightforward to synthesize and characterize, and it has been studied across an unusually wide set of rodent injury models with reported effects on histological and functional endpoints. The rodent gastrointestinal lesion literature in particular spans three decades and includes a variety of induction methods. Reported toxicity in rodents has been low across the doses examined in that literature.

What remains preliminary: essentially everything about human physiology. There is no completed, peer-reviewed, controlled clinical trial of BPC-157 in humans. Pharmacokinetics in humans have not been characterized in the published literature, so absorption, distribution, half-life, and clearance are unknown. Long-term safety in humans is unstudied. The angiogenic hypothesis, if correct, would carry the same theoretical considerations that apply to any pro-angiogenic signal, and those have not been evaluated.

The literature also has a structural weakness that readers should weigh directly. A large fraction of the published work traces back to the Zagreb group and its collaborators, and independent replication by unaffiliated laboratories is sparse relative to the volume of publications. This is not an accusation of error. It is a statement about how much of the evidence is statistically independent, and the honest answer is less than the publication count implies. Several published reviews of the peptide have raised the same concern.

For a researcher planning work with this compound, the practical implication is that BPC-157 is a reasonable subject for mechanistic and preclinical investigation and is not a compound about which any human conclusion can currently be drawn. Response BioLabs states that plainly because the alternative, letting the size of the rodent literature stand in for human evidence, is how this compound has been misrepresented for a decade.

The lyophilized powder is hygroscopic. Vials should be brought to room temperature before opening so that atmospheric moisture does not condense onto cold powder, and they should be resealed promptly. Long-term inventory is held at -20 C or below. Short-term working inventory at 2 to 8 C is acceptable for the dry powder, which is considerably more stable than any solution of it.

For reconstitution in a laboratory setting, bacteriostatic water is the common diluent for research peptides, added slowly against the inside wall of the vial rather than directly onto the powder cake. The vial should be swirled gently or left to dissolve on its own. Vortexing and vigorous shaking introduce shear and air-liquid interface stress that can degrade peptides and promote aggregation. Once in solution, the material is kept at 2 to 8 C and protected from light.

Aliquoting is the single most useful practice for preserving a reconstituted stock. Repeated freeze and thaw cycles are a common source of quiet potency loss that will not be visible in the vial. Single-use aliquots at the working concentration, labeled with the compound, lot number, concentration, diluent, and date of reconstitution, remove that variable and make experimental results traceable. Any discoloration, visible particulate, or cloudiness in a previously clear solution is a reason to discard rather than to investigate mid-experiment.